secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-08-06T20:02:32+00:00
Accession:  0001171843-26-005317
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q2 2026 net loss of $18.0M; cash $215.2M, runway into 2Q28
-------------------------------------------------------------------------

- Net loss $18.0M in Q2 2026 vs $8.0M in Q2 2025; R&D expenses $16.0M vs $7.9M.
- Cash, equivalents and marketable securities $215.2M at June 30, 2026 (incl. $189.4M from Jan 2026 financing) vs $56.8M at Dec 2025; runway into 2Q28.
- Soquelitinib Phase 3 PTCL and Phase 2 atopic dermatitis enrollment on track; plans to start hidradenitis suppurativa and asthma trials later 2026.
- Invested $5.0M in Angel Pharma equity financing for soquelitinib trials in China.
- Angel Pharma to initiate Phase 2 asthma trial early 2027; Corvus to start Phase 1b hidradenitis suppurativa and Phase 2 asthma trials later 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/0001171843-26-005317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184326005317/f8k_080626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer